Health Care

On The Move Sizzling Stocks: CytRx Corporation (NASDAQ:CYTR), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

0 69

CytRx Corporation (NASDAQ:CYTR) initiated the shares trading at $0.64 and showed negative change of -29.92% while the stock’s final trade was registered at $ 0.63. However, its previous closing price was seen at $0.90. The stock negotiated total number of 17.65 million shares as compared to 3 months average volume of 2.03 million shares.

The stock price demonstrated downbeat change from its 50 day moving average of 2.25 and had been down from its 200 Day Moving Average of 2.48.

CytRx Corporation (CYTR), a biopharmaceutical research and development firm specializing in oncology, recently reported that it has priced a registered public offering of an aggregate of about 28.6 million shares of ordinary stock at a price to the public of $0.70 per share.  Investors will also receive warrants to purchase up to an aggregate of about 28.6 million shares of ordinary stock with an exercise price of $0.70 per share.  The warrants are immediately exercisable and have a term of exercise of 12 months.  The offering is predictable to close on or about July 20, 2016, subject to the satisfaction of customary closing conditions.

The average true range of CytRx Corporation’s (CYTR) is recorded at 0.27 and the relative strength index of the stock stands 19.93. The stock price is going below to its 52 week low with -14.86% and lagging behind from its 52 week high with -85.00%. Analyst recommendation for this stock stands at 2.00. A look on the firm performance, its monthly performance is -72.61% and a quarterly performance of -80.37%. The stock price is trading downbeat from its 200 days moving average with -75.80% and down from 50 days moving average with -73.95%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “1” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.5” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) climbed +5.59% and ended at $5.10 greater than previous closing price of $4.83. The total 1.76 million shares were bought and sold throughout the most recent trading session more than average volume of 938.72 thousand shares.

Progenics Pharmaceuticals, Inc.’s (PGNX) has price to sale ratio of 32.55. . A look on the firm performance, its monthly performance is 10.15% and a quarterly performance of 4.72%. The stock price is moving up from its 20 days moving average with 7.63% and isolated positively from 50 days moving average with 6.31%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago,  shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter